Login / Signup

A novel way to quantify schizophrenia symptoms in clinical trials.

Oleg N MedvedevMichael BerkOlivia M DeanEllie BrownMargaret H SandhamJoanna F DipnallRobert K McNamaraAlexander SumichChristian U KrägelohAjit NarayananRichard J Siegert
Published in: European journal of clinical investigation (2020)
Identified dynamic symptoms are more amendable to change and should be the primary target of interventions aiming at effectively treating schizophrenia. Separating out the dynamic symptoms would increase assay sensitivity in trials, reduce the signal to noise ratio and increase the potential to detect the effects of novel therapies in clinical trials.
Keyphrases
  • clinical trial
  • bipolar disorder
  • sleep quality
  • physical activity
  • phase ii